Focus Partners Wealth
ALNY icon

Focus Partners Wealth’s Alnylam Pharmaceuticals ALNY Stock Holding History

Focus Partners Wealth’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.43M Sell
4,743
-59
-1% -$17.8K ﹤0.01% 1489
2026
Q1 		$1.59M Sell
4,802
-2,281
-32% -$776K ﹤0.01% 1419
2025
Q4 		$2.82M Buy
7,083
+466
+7% +$206K ﹤0.01% 1184
2025
Q3 		$2.99M Buy
6,617
+3,467
+110% +$1.41M ﹤0.01% 900
2025
Q2 		$1.03M Sell
3,150
-1,068
-25% -$296K ﹤0.01% 1131
2025
Q1 		$1.14M Sell
4,218
-209
-5% -$53.7K ﹤0.01% 1019
2024
Q4 		$1.04M Buy
4,427
+3,144
+245% +$827K ﹤0.01% 1047
2024
Q3 		$353K Sell
1,283
-210
-14% -$54.7K ﹤0.01% 1274
2024
Q2 		$363K Buy
+1,493
New +$236K ﹤0.01% 1020

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Focus Partners Wealth's ALNY Position: Q2 2026 in Review

Focus Partners Wealth reduced its Alnylam Pharmaceuticals (ALNY) stake by 1.2% in Q2 2026, selling an estimated $17.8K and leaving 4,743 shares worth $1.43M. The position accounts for ﹤0.01% of the portfolio, ranked #1489.

Focus Partners Wealth first reported a position in ALNY in Q2 2024 and has held it in 9 quarters since. The position peaked at $2.99M in Q3 2025. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Focus Partners Wealth held 4,743 shares of Alnylam Pharmaceuticals worth $1.43M as of Q2 2026.
  • Focus Partners Wealth sold 59 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $17.8K.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Focus Partners Wealth's portfolio in Q2 2026, its #1489 holding.
  • Focus Partners Wealth first reported a position in Alnylam Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
  • Focus Partners Wealth's Alnylam Pharmaceuticals position peaked at $2.99M in Q3 2025.
  • 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Focus Partners Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.